This inventor holds 100 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Pharmaceutical Chemistry (CPC class C07D-). Top assignees: Bayer Aktiengesellschaft, Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft. Active years: 1984-2012.
Inventors with similar research interests:
Location History:
- Wuppetal, DE (1998)
- Wuppertal, DE (1984 - 2012)
Company Filing History:
96 out of 12,266 
1 out of 721 
1 out of 386 
Years Active: 1984-2012
Areas of Expertise:
Title: The Innovative Contributions of Hilmar Bischoff in Cardiovascular Medicine
Introduction
Hilmar Bischoff, a prominent inventor based in Wuppertal, Germany, has significantly impacted the field of cardiovascular medicine through his extensive research and innovative contributions. With an impressive portfolio of 100 patents, Bischoff has focused on developing novel compounds that address various cardiovascular disorders.
Latest Patents
Among his latest inventions are the "Substituted Chromanol Derivatives and Their Use" and "Chemical Compound and Its Use." The first invention centers around substituted chromanol derivatives aimed at treating and preventing diseases, particularly cardiovascular disorders. This invention outlines the preparation processes and the medicinal applications of these compounds. The second patent introduces a novel tetrahydroquinoline derivative, which serves as an inhibitor of the cholesterol ester transfer protein (CETP), targeting conditions such as hypolipoproteinaemias and hypercholesterolaemias. Both patents highlight Bischoff's commitment to advancing cardiovascular therapeutics.
Career Highlights
Bischoff has had a significant career path, during which he worked at Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company. His tenure at Bayer has been crucial in shaping his research and development capabilities, enabling him to drive innovations in the pharmaceutical field.
Collaborations
Throughout his career, Hilmar Bischoff has collaborated with notable colleagues, including Delf Schmidt and Rolf Angerbauer. These collaborations have fostered a dynamic environment for sharing ideas and advancing innovative solutions in cardiovascular health.
Conclusion
Hilmar Bischoff's work continues to pave the way for groundbreaking developments in the treatment and prevention of cardiovascular diseases. With a remarkable number of patents and a solid foundation in research and collaboration, he remains a significant figure in the pharmaceutical industry, dedicated to improving global health outcomes.